PPCB Propanc Biopharma, Inc.
Listings ·
Nasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million.
Propanc Biopharma received a Nasdaq notice that its stock has been below the $1.00 minimum bid price, and it has until June 30, 2026 to regain compliance. Its latest annual report showed cash of $12,088 at June 30, 2025.
Propanc sold 1,000,000 shares at $4.00 each, while its prospectus carries a going-concern warning and reports $50,760 of cash on March 31, 2025. The stock left the OTC Pink market for the Nasdaq Capital Market.
Propanc Biopharma sold a $112,350 convertible note to 1800 Diagonal Lending LLC for $107,000. The note bears 22% interest, matures April 30, 2026 and converts at a 25% discount after 180 days, in a stock its last annual report says was quoted at $0.0003.
Propanc Biopharma, Inc. is a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors using pancreatic proenzymes that target cancer stem cells in patients with pancreatic, ovarian and colorectal cancers. Its lead product candidate, PRP, is an intravenous injection combining two proenzymes, trypsinogen and chymotrypsinogen, in a synergetic ratio. The text says PRP is designed to treat early-stage cancer and pre-cancerous diseases, and as a preventative measure for patients at risk of cancer based on genetic screening. The company says it has conducted successful pre-clinical studies on PRP and has begun preparing a clinical study in advanced cancer patients. It plans to submit a clinical trial application in the fourth quarter of 2026 and, subject to raising additional capital, to start a First-In-Human Phase Ib study in the first half of 2027. PRP received FDA Orphan Drug Designation for pancreatic cancer in June 2017. Its POP1 joint research program, with the universities of Jaén and Granada, is designed to produce a backup clinical compound to PRP.
| Product or program | What it is | Stage |
|---|---|---|
| PRP | Intravenous combination of trypsinogen and chymotrypsinogen proenzymes for cancer | Pre-clinical studies completed; clinical study being prepared |
| POP1 Program | Joint research and drug discovery program for a backup clinical compound to PRP | Research program |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $625,477 | $223,721 |
| Net income (loss) | -$18.9 million | -$58.9 million |
| Cash from operations | -$5.7 million | -$405,168 |
Our latest story on this, dated Oct 29, 2026: "Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 29, 2026: "Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 18, 2025: "Propanc Biopharma prices $4 million offering and moves to Nasdaq". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 18, 2025: "Propanc Biopharma prices $4 million offering and moves to Nasdaq". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 30, 2025: "Propanc Biopharma sells $112,350 convertible note for $107,000, with 22% annual interest". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 7, 2026: "Propanc Biopharma gets Nasdaq minimum bid price deficiency notice, has until June 30, 2026". The story links the filing or release it is based on. Read the story.
Propanc Biopharma, Inc. trades under the ticker PPCB on NASDAQ.
Propanc Biopharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Propanc Biopharma, Inc. is 1517681. Its filings are on SEC EDGAR.
6,331,116 shares as of 2026-09-23, per the cover page of its 10-K filed 2026-09-25.
Our directory records Propanc Biopharma, Inc. under Australia.
Our directory classifies Propanc Biopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Propanc Biopharma, Inc. is US74346N8002.
aibio.space lists Propanc Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 424B4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio